XYWAV

Phase 2Small molecule

LLeiden University Medical Center

XYWAV is one of 8 small molecule programs targeting Cerebral Amyloid Angiopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral Amyloid AngiopathyActive, not recruiting

Cerebral Amyloid AngiopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Cerebral Amyloid Angiopathy

#DrugCompanyPhaseTrials

Minocin

TTriax

Approved

—2

Colcrys

Alnylam Pharmaceuticals

Phase 2

1 3

Amyloid PET

NNational Taiwan University Hospital

Phase 3

1 4

RG6026

Bayer Aspirin

Plavix

ALN-APP

Alnylam Pharmaceuticals

Phase 2

1 8

XYWAV

LLeiden University Medical Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cerebral Amyloid Angiopathy1 trial

Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy

Enrolling by invitation·LLeiden University Medical Center·Phase 2·NCT06421532·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for XYWAV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XYWAV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XYWAV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Leiden University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLeiden University Medical Center

XYWAV

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cerebral Amyloid Angiopathy1 trial

References

Drug Info

Quick Facts

Related News